Enliven Therapeutics (ELVN) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free ELVN Stock Alerts $24.49 -0.21 (-0.85%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 4,875 Shares of Stockmarketbeat.com - May 8 at 9:23 PMBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - May 8 at 6:52 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 1,000 Shares of Stockmarketbeat.com - May 7 at 9:09 PMEnliven Therapeutics (NASDAQ:ELVN) Trading 6.2% Higher marketbeat.com - May 7 at 6:22 PMBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - May 3 at 5:44 AMJoseph P. Lyssikatos Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockamericanbankingnews.com - May 3 at 5:04 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $55,152.50 in Stockinsidertrades.com - May 2 at 6:39 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Sees Significant Growth in Short Interestamericanbankingnews.com - May 2 at 3:42 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Sharesmarketbeat.com - May 1 at 7:51 PMEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volumemarketbeat.com - April 30 at 6:48 PMShort Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Expands By 9.7%marketbeat.com - April 30 at 9:35 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares of Stockamericanbankingnews.com - April 30 at 4:24 AMSamuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - April 30 at 4:22 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $202,680.00 in Stockmarketbeat.com - April 29 at 7:12 PMEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.5%marketbeat.com - April 29 at 4:35 PMCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using Optionsnasdaq.com - April 28 at 10:04 AMBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potentialmarkets.businessinsider.com - April 26 at 5:23 PMBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant Patientsmarkets.businessinsider.com - April 26 at 7:22 AMMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investorsfinance.yahoo.com - April 19 at 3:21 PMEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increasemarketbeat.com - April 19 at 2:56 PMEnliven Therapeutics files to sell 6.43M shares for holdersmsn.com - April 18 at 10:31 PMEnliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher marketbeat.com - April 18 at 1:56 PMEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02msn.com - April 17 at 9:16 PMEnliven Therapeutics CMO sells $501k in company stockinvesting.com - April 16 at 10:49 PMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Sharesinsidertrades.com - April 16 at 6:24 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in Stockinsidertrades.com - April 16 at 4:46 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of Stockmarketbeat.com - April 15 at 9:40 PMEnliven Therapeutics (NASDAQ:ELVN) Shares Down 3.6% After Insider Sellingmarketbeat.com - April 15 at 10:35 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 53,400 Shares of Stockinsidertrades.com - April 13 at 7:07 AMEnliven reports promising Phase 1 data for leukemia druginvesting.com - April 12 at 10:46 PMStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market Potentialmarkets.businessinsider.com - April 11 at 10:55 PMEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Programfinance.yahoo.com - April 11 at 5:50 PMEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursdaymsn.com - April 11 at 12:46 PMEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer Drugmarketwatch.com - April 11 at 12:46 PMEnliven Therapeutics shares rise on promising preliminary data for blood cancer drugproactiveinvestors.com - April 11 at 12:25 PMEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High at $26.00marketbeat.com - April 11 at 10:45 AMEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemiaglobenewswire.com - April 11 at 7:55 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Sharesinsidertrades.com - April 11 at 6:48 AMEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 3.5%marketbeat.com - April 10 at 3:24 PMEnliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Saysmarkets.businessinsider.com - April 9 at 6:56 PMEnliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directorsglobenewswire.com - April 9 at 4:05 PMOwning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),finance.yahoo.com - April 9 at 8:55 AMMizuho Begins Coverage on Enliven Therapeutics (NASDAQ:ELVN)marketbeat.com - April 9 at 8:23 AMRahul D. Ballal Sells 3,485 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - April 9 at 4:46 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,485 Shares of Stockmarketbeat.com - April 8 at 9:21 PMEnliven Therapeutics (NASDAQ:ELVN) Trading Down 3.9%marketbeat.com - April 8 at 1:46 PMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,237 Shares of Stockinsidertrades.com - April 4 at 6:50 AMRahul D. Ballal Sells 3,237 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockmarketbeat.com - April 4 at 12:21 AMEnliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher marketbeat.com - April 1 at 3:29 PMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stockmarketbeat.com - March 29 at 6:48 PM Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. ELVN Media Mentions By Week ELVN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.430.36▲Average Medical News Sentiment ELVN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼101▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 89bio News Today Tango Therapeutics News Today Arcutis Biotherapeutics News Today Sage Therapeutics News Today Immunome News Today ARS Pharmaceuticals News Today Zentalis Pharmaceuticals News Today OPKO Health News Today ALX Oncology News Today Longboard Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
